Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854
Debt
Debt-to-Equity Ratio0.31
Current Ratio5.01
Quick Ratio3.93
Price-To-Earnings
Trailing P/E Ratio48.49
Forward P/E Ratio50.34
P/E Growth3.4
Sales & Book Value
Annual Sales$642.99 million
Price / Sales11.59
Cash Flow$5.7637 per share
Price / Cash34.24
Book Value$28.72 per share
Price / Book6.87
Profitability
EPS (Most Recent Fiscal Year)$4.07
Net Income$126.15 million
Net Margins19.50%
Return on Equity14.64%
Return on Assets9.53%
Miscellaneous
Employees2,000
Outstanding Shares37,760,000
Market Cap$7.54 billion
BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions
What is BIO-TECHNE's stock symbol?
BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."
How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?
BIO-TECHNE announced a quarterly dividend on Wednesday, August 8th. Shareholders of record on Friday, August 17th will be given a dividend of $0.32 per share on Friday, August 31st. This represents a $1.28 annualized dividend and a yield of 0.65%. The ex-dividend date of this dividend is Thursday, August 16th. View BIO-TECHNE's Dividend History.
How were BIO-TECHNE's earnings last quarter?
BIO-TECHNE Corp (NASDAQ:TECH) released its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported $1.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.05. The biotechnology company earned $180.25 million during the quarter, compared to analyst estimates of $176.24 million. BIO-TECHNE had a return on equity of 14.64% and a net margin of 19.50%. View BIO-TECHNE's Earnings History.
When is BIO-TECHNE's next earnings date?
What price target have analysts set for TECH?
6 analysts have issued 1 year price objectives for BIO-TECHNE's shares. Their predictions range from $165.00 to $215.00. On average, they expect BIO-TECHNE's stock price to reach $191.8333 in the next year. This suggests that the stock has a possible downside of 2.8%. View Analyst Price Targets for BIO-TECHNE.
What is the consensus analysts' recommendation for BIO-TECHNE?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.
Who are some of BIO-TECHNE's key competitors?
Some companies that are related to BIO-TECHNE include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Repligen (RGEN), Halozyme Therapeutics (HALO) and Acceleron Pharma (XLRN).
Who are BIO-TECHNE's key executives?
BIO-TECHNE's management team includes the folowing people:
- Mr. Charles R. Kummeth, Pres, CEO & Director (Age 58)
- Mr. James T. Hippel, Sr. VP of Fin., CFO & Principal Accounting Officer (Age 47)
- Mr. N. David Eansor, Sr. VP of Biotechnology Division (Age 57)
- Mr. Robert M. Gavin, Sr. VP of Protein Platforms Division (Age 50)
- Mr. Kevin S. Gould, Sr. VP of Diagnostics Division (Age 52)
Has BIO-TECHNE been receiving favorable news coverage?
Media stories about TECH stock have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. BIO-TECHNE earned a daily sentiment score of 0.18 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for BIO-TECHNE.
Who are BIO-TECHNE's major shareholders?
BIO-TECHNE's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.05%), Schroder Investment Management Group (5.89%), Janus Henderson Group PLC (3.71%), Massachusetts Financial Services Co. MA (1.59%), Riverbridge Partners LLC (1.37%) and DF Dent & Co. Inc. (1.36%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, Charles R Kummeth, John L Higgins, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.
Which institutional investors are selling BIO-TECHNE stock?
TECH stock was sold by a variety of institutional investors in the last quarter, including Select Equity Group L.P., Epoch Investment Partners Inc., Castleark Management LLC, Royce & Associates LP, Sandler Capital Management, Quantum Capital Management, Bank of America Corp DE and Macquarie Group Ltd.. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Charles R Kummeth, John L Higgins, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for BIO-TECHNE.
Which institutional investors are buying BIO-TECHNE stock?
TECH stock was acquired by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Advisors Asset Management Inc., BTIM Corp., OppenheimerFunds Inc., Massachusetts Financial Services Co. MA, Fred Alger Management Inc., BlackRock Inc. and Janus Henderson Group PLC. View Insider Buying and Selling for BIO-TECHNE.
How do I buy shares of BIO-TECHNE?
Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIO-TECHNE's stock price today?
One share of TECH stock can currently be purchased for approximately $197.35.
How big of a company is BIO-TECHNE?
BIO-TECHNE has a market capitalization of $7.54 billion and generates $642.99 million in revenue each year. The biotechnology company earns $126.15 million in net income (profit) each year or $4.07 on an earnings per share basis. BIO-TECHNE employs 2,000 workers across the globe.
How can I contact BIO-TECHNE?
BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]
MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
